A new avenue for research into rheumatoid arthritis (RA) has been revealed by researchers at the University of Birmingham, and the folks behind the findings believe it may lead to new treatment options.
What they identified is a subset of Synovial Fibroblasts (SFs), which are the cells that make up part of the connective tissue, or synovium, around human joints. In people with RA, SF cells cause damage by invading and attacking the cartilage and bone around the joint.
The researchers identified two distinct types of SF within the synovial membrane. They showed that these cell types, defined by the presence of specific cell surface markers (PDPN and CD248), aggregate in different layers of the synovium, and just one (the PDPN type) is responsible for cartilage damage in RA patients.
“This study not only shows the existence of distinct sub-sets of synovial fibroblasts, but also suggests that these cells are able to self-organize into lining and sub-lining layers in the presence of cartilage,” said Dr. Adam Croft from the University of Birmingham. “Combined with the difference in migration rates between the two types of cell, these results are extremely promising in terms of finding new therapeutic targets for treatment of rheumatoid arthritis.”
During the study, SF cells from RA patients were grown in vitro within an artificial synovium, then “activated”’ using stress-inducing proteins called cytokines. The artificial synovium containing the SFs was then inserted into a mouse (whose own immune system had been “switched off”), along with human cartilage to simulate a joint, to see how the SF cells would develop in vivo.
Following implantation, tests showed that the lining layer of the artificial synovium (i.e. the part closest to the cartilage) contained invasive PDPN type SFs, while the part that was further away from the cartilage contained the non-invasive CD248 type.
The study also confirmed recent findings that activated SF cells can migrate through blood vessels to attack other cartilage in the body. The researchers built on these findings by showing that PDPN type SF cells were the first to migrate, with CD248 cells only appearing in secondary tissue at a later stage.
Current treatment for RA involves giving patients a combination of immunosuppressive drugs, which can have a serious impact on quality of life. The results of this study suggest that targeting SF cells processes could make future treatments not only more effective, but also more manageable for patients.